US 12,318,413 B2
Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
Jennifer Wargo, Houston, TX (US); and Vancheswaran Gopalakrishnan, Houston, TX (US)
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed by BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed on Jul. 22, 2022, as Appl. No. 17/814,314.
Application 17/814,314 is a division of application No. 16/337,820, granted, now 11,395,838, previously published as PCT/US2017/053717, filed on Sep. 27, 2017.
Claims priority of provisional application 62/400,372, filed on Sep. 27, 2016.
Claims priority of provisional application 62/508,885, filed on May 19, 2017.
Claims priority of provisional application 62/557,566, filed on Sep. 12, 2017.
Prior Publication US 2023/0109343 A1, Apr. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/741 (2015.01); A61K 9/00 (2006.01); A61K 35/00 (2006.01); A61K 35/17 (2025.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C12N 1/20 (2006.01); C12Q 1/04 (2006.01)
CPC A61K 35/741 (2013.01) [A61K 9/0053 (2013.01); A61K 35/17 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C12N 1/20 (2013.01); C12Q 1/04 (2013.01); A61K 2035/115 (2013.01)] 23 Claims
 
1. A method of treating a cancer in a human subject in need thereof comprising administering a therapeutically effective amount of a human programmed cell death 1 (PD-1) axis binding antagonist to the subject, wherein the subject has been determined to have an increased relative abundance, or the same or substantially the same relative abundance, of bacteria belonging to the family Ruminococcaceae in their gut microbiome compared to one or more other human subjects having the cancer and the one or more subjects respond to therapy with the human PD-1 axis binding antagonist, and wherein the administering treats the cancer in the human subject.